Most cells in the liver are polyploid, but the functional role of polyploidy is unknown. Polyploidization normally occurs through cytokinesis failure and endoreduplication around the time of weaning. To interrogate the function of polyploidy while avoiding irreversible manipulations of essential cell cycle genes, we developed multiple orthogonal mouse models to transiently and potently alter liver ploidy. Premature weaning, as well as in vivo knockdown of E2f8 or Anln, allowed us to toggle between diploid and polyploid states. While there was no impact of ploidy alterations on liver function, metabolism, or regeneration, hyperpolyploid mice suppressed and hyperdiploid mice accelerated tumorigenesis in mutagen and high fat induced models.
Introduction
Polyploid cells and organisms contain more than two homologous sets of chromosomes.
Polyploidy is prevalent in plants, fish, and salamanders 1 , but rare in mammals except in the cells of the heart, marrow, and liver. Up to 90% of rodent and 50% of human hepatocytes are polyploid 2, 3 . In rodents, liver ploidy dramatically increases around weaning (P14-P21) and continues to increase with age 4, 5 . The dominant mechanism for polyploidization is cytokinesis failure that leads to binucleated hepatocytes 5 . To a lesser extent, hepatocyte endoreduplication also contributes to polyploidy via replication of the nuclear genome in the absence of cell division 6 . Thus, polyploid hepatocytes (tetraploids, octoploids, etc.) can be bi-or mononuclear.
Postnatal liver polyploidization is developmentally regulated, but ploidy is dynamic and can increase with surgery 7 , fatty liver disease, and oxidative stress 8 . Despite these observed correlations, the extent to which ploidy influences cellular or tissue function remains completely unknown.
Many hypotheses have been proposed for the existence of polyploid cells. In yeast and plants, polyploidy promotes adaptation to environmental stresses, in some cases through the production of genetically diverse aneuploid daughter cells 9, 10 . Recently, it was shown that a subset of polyploid hepatocytes undergo reductive cell divisions prone to missegregation, leading to the accumulation of aneuploid cells 11 . Though the prevalence of aneuploidy in the liver is debated 12 , aneuploidy may represent a means by which genetic diversity and premalignancy can evolve.
Whether or not polyploidy is a risk for or protective against cancer is unknown. In support of the premalignancy concept, Fujiwara et al. showed that tetraploidy in p53 null mouse mammary epithelial cells is a chromosomally unstable state that predisposes to transformation, but the relevance to wild-type tetraploid hepatocytes is unclear 13 . As an argument against increased cancer risk, the polyploid state has been associated with terminal differentiation and limited proliferation 14 .
Also, Ganem et al. demonstrated that tetraploid hepatocyte proliferation/transformation is suppressed by the Hippo pathway 15 , but we and others have shown that 4c and 8c hepatocytes divide efficiently and contribute as much to proliferation, growth, and regeneration as 2c cells in vivo (Extended Data Fig. 1a ) 11 . Despite the hypothetical risks and benefits of polyploidy, whether tetraploid or diploid hepatocytes are more prone to cancer remains untested and thus the functional contributions of polyploidy to liver physiology, injury, and cancer remain completely unknown.
Defects in genes required for cell cycle or cytokinesis (Trp53, Rb, or Cdk1) can dramatically alter ploidy [16] [17] [18] , but interrogation of mice with these germline mutations cannot distinguish the effects of ploidy from the effects of profound cell cycle deficiencies. For example, Cdk1 knockout (KO) hepatocytes cannot complete mitosis and are dramatically polyploid (up to 32N or greater). As a consequence, liver-specific Cdk1 KO mice are unable to undergo malignant transformation, but whether this is specifically due to polyploidy or permanent Cdk1 deficiency is unclear 18 . In contrast, E2f7/E2f8 double KO livers are almost entirely comprised of diploid hepatocytes, but these mice have no physiological or regenerative phenotypes 19, 20 , suggesting that polyploidy is dispensable for liver development and regeneration after acute damage. Recently, E2f8 KO livers were shown to accelerate tumorigenesis, but it is unknown if this is due to transcriptional effects of E2f8 deficiency or to the diploid state of E2f8 KO hepatocytes 21 . Likewise, Zhang et al.
showed that Yap activation promotes polyploidy and cancer, but it is unclear if the ploidy itself directly impacts tumor biology independent of Yap 22 . Due to the lack of appropriate tools and the inability to assess the chronic impact of ploidy change, the role polyploidy plays in diseases involving long-term cell division cycles remains unclear. Here, we developed multiple methods and in vivo reagents to transiently, reversibly alter ploidy and found that the polyploid state suppressed liver tumorigenesis by buffering against tumor suppressor loss.
Premature weaning promoted polyploidy and was protective against HCC development
To answer these questions, we reasoned that the transient, reversible control of ploidy state would represent a fundamental advance to enable the elucidation of ploidy functions. Since the predominant mechanism of widespread hepatocyte polyploidization is cytokinesis failure, a phenomenon temporally associated with weaning in rats 23 , we asked if differential weaning times could transiently influence ploidy in mice. By weaning wild-type (WT) mice at P13 (premature weaning) or P21 (normal weaning) ( Fig. 1a ), we found that prematurely weaned mice had significantly more binucleated hepatocytes ( Fig. 1b ) and increased cellular ploidy ( Fig. 1c ) at 19 days of age. To induce hepatocellular carcinoma (HCC), we gave a single intraperitoneal (IP) dose (25g/g) of the agent diethylnitrosamine (DEN) to both cohorts at P19, a time point when ploidy states were divergent. Five months later, pre-weaned mice with greater ploidy at P19 exhibited significantly reduced gross and microscopic tumor burden ( Fig. 1d, e ), suggesting that polyploidy could exert tumor suppressive effects. Since weaning is confounded by factors other than ploidy, we also used additional methods to control ploidy state.
In vivo siRNAs revealed that the polyploid state protected against tumorigenesis
To inducibly toggle polyploidy without introducing permanent genetic lesions, we used siRNA to transiently knockdown genes that affect ploidy. We targeted Anillin (Anln), an actin binding protein required for cytokinesis 24 (Extended Data Fig. 1b , c) and E2f8, a transcription factor required for polyploidization 20 . In vivo, Anln and E2f8 siRNA vs. scramble siRNA (siCtrl) delivery in lipid nanoparticles from P10-P20 25 resulted in significant knockdown of Anln and E2f8 mRNA and protein ( Fig. 2a, b and Extended Data Fig. 1d ). As expected, cellular ploidy was significantly increased after Anln knockdown and decreased after E2f8 knockdown ( Fig. 2c ). Confocal imaging based ploidy characterization revealed that siAnln treated livers had significantly larger cell and nuclear size, while the siE2f8 treated livers showed the opposite (Fig. 2d, e ). Since cell and nuclear size correlate with DNA content, this suggested significant ploidy changes. To quantitatively distinguish mono-vs. binucleated tetraploids, we integrated flow and confocal imaging data ( Fig. 2f ). This revealed that siAnln hepatocytes were 32% mononuclear diploid, 32% mononuclear tetraploid, and 32% binuclear tetraploid. siE2f8 hepatocytes were 64% mononuclear diploid, 17% mononuclear tetraploid, and 16% binuclear tetraploid. Furthermore, a
Florescence In Situ Hybridization (FISH) assay confirmed the existence of mono-and binuclear tetraploids ( Fig. 2g, h ). Overall, this indicated that both mononuclear and binuclear tetraploids were increased in siAnln vs. control livers and in control vs. siE2f8 livers.
Altered ploidy did not impact overall health, liver mass, body mass, hepatocyte differentiation, CYP450 expression, or proliferation (Extended Data Fig. 2a-e ). Moreover, we challenged these mice to acute regeneration assays such as partial hepatectomy and hepatotoxin treatments.
Liver/body weight ratios after 2/3 rds partial hepatectomy were not significantly different between different ploidy groups (Extended Data Fig. 3a ). No differences in necrosis and proliferation arose after one dose of DEN or carbon tetrachloride (CCl4) (Extended Data Fig. 3b , c). These results showed that polyploid and diploid hepatocytes were equivalently able to survive, recover, and proliferate after injuries. These findings are consistent with previous studies in mice with ploidy alterations 19, 20 , again demonstrating that ploidy state has minimal influences on post-natal liver growth and regeneration, likely because only 2-4 cell division cycles are required for recovery after these profound, acute injuries.
Having established that inducible inhibition of Anln and E2f8 allowed us to alter ploidy without introducing irreversible genetic mutations, we next evaluated the impact of ploidy on tumor development. We injected DEN (75g/g x 1 dose) into mice four days after the last dose of siCtrl, siAnln, or siE2f8 (siRNA delivery schema in Fig. 2a ). Six months later, siE2f8 treated hyperdiploid livers had significantly increased gross tumor burden, microscopic tumor nodules, and liver/body weight ratio than siCtrl livers (Fig. 2i , j and Extended Data Fig. 4a -c). In contrast, siAnln treated hyperpolyploid livers showed the opposite. Altogether, these findings suggested that the degree of liver polyploidy is inversely proportional to the efficiency of carcinogenesis. To further exclude the possibility of a residual siRNA effect, we also introduced DEN starting at 14, rather than 4 days, after the last siRNA injection. Again, polyploidy demonstrated a potent tumor suppressive effect ( Fig. 2k and Extended Data Fig. 4d ).
E2f8 knockout and inducible Anln shRNA mice protect against HCC in multiple models
Given the formal possibility that siRNAs or lipid nanoparticles could have off-target or nonspecific effects, we also used Cas9 to generate whole-body E2f8 KO mice (Extended Data Fig.   5a ), which have predominantly diploid hepatocytes in adulthood ( Fig. 3a) . Interestingly, we observed that E2f8 WT, Het and KO livers had equivalent levels of ploidy at P15, and only diverged in ploidy state by P27 ( Fig. 3a ). We hypothesized that if ploidy is a specific and essential factor causing tumor suppression in E2f8 KO livers, then mutagenizing and inducing cancer at P15 would not result in differences in HCC development, while inducing at P27 would result in large differences. Indeed, DEN given at P15 (25g/g) resulted in no cancer differences between the three groups, while DEN at P27 (75g/g) caused more HCCs in E2f8 Het and E2f8 KO mice when compared to E2f8 WT mice ( Fig. 3b -e, Extended Data Fig. 5b ). These results further demonstrated that the E2f8 gene itself contributed little to cancer development independent of the differences in ploidy seen at P27.
Next, we wanted to generate a more potent and versatile mouse model to increase polyploidy. In addition, our goals were to drive greater levels of polyploidy and to employ a small inhibitory shRNA distinct from the siAnln used above in order to corroborate on target effects on Anln.
Thus, we created a doxycycline (dox)-inducible transgenic mouse expressing an shRNA against
Anln. Transgenic mice were derived from embryonic stem cells containing Rosa-rtTA and a GFP + shAnln cassette under the control of a tetracycline responsive promoter element (TRE) (Extended Data Fig. 6a, b ; transgenic design based on Scott Lowe's group 26 ). Dox could be used to induce Anln suppression in a temporally specific fashion ( Fig. 4a ).
Rosa-rtTa alone or
Rosa-rtTa; TRE-shAnln (hereafter called Rosa and TG-shAnln) transgenic mice exposed to dox water from P0-P20 showed normal growth, development, and liver function (Extended Data Fig. 6c-e). Anln mRNA levels were suppressed by 50% ( Fig. 4b ), which resulted in hyperpolyploid livers at multiple time points after dox withdrawal ( Fig. 4c-e ). These livers were similar to what was seen with Anln siRNA treatment, but had more profound levels of polyploidization. In addition, GFP protein (and likely Anln shRNA) completely disappeared by 15 days after dox withdrawal ( Fig. 4f ), demonstrating the reversibility of Anln suppression.
Hyperpolyploid mice derived from transient suppression of Anln were almost completely protected from DEN induced HCC development, confirming the siRNA results ( Fig. 4g , h). We then wanted to exploit this model to analyze the function of polyploidy in a carcinogenesis model caused by another clinically important mechanism. Steatohepatitis represents an increasingly relevant risk factor for HCC and has been associated with an increase in polyploidy 8 . To induce long term fatty liver disease and HCC, we fed mice with high fat diet (HFD) after transiently inducing ploidy changes ( Fig. 4i ). After eight months, Rosa and TG-shAnln mice had similarly high levels of steatosis and liver function abnormalities ( Fig. 4j -l and Extended Fig. 6f ), but 50% of control mice while no hyperpolyploid mice developed HCC ( Fig. 4m , n). In summary, multiple murine models increasing and decreasing ploidy corroborated the fact that higher levels of polyploidy suppressed HCC formation in diverse cancer models.
Polyploids were protected from tumor suppressor LOH but not oncogene activation
To probe underlying mechanisms in the DEN HCC model, we first asked if ploidy significantly regulated metabolic properties that would influence tumorigenesis. DEN is first bioactivated by CYP450 family enzymes to become α-hydroxylnitrosamine 27 . Expression of CYP450 enzymes in general and zonation of Cyp2e1 in particular were unchanged in livers with distinct ploidy (Extended Data Fig. 3c and Extended Data Fig. 7a ). Elevated levels of reactive oxygen species (ROS) secondary to hepatotoxins are known to accelerate tumor initiation 28 , but ROS levels were unchanged between siRNA treated mice and between E2f8 WT/Het/KO mice, before and after DEN (Extended Data Fig. 7b , c). It is also known that following the DEN bioactivation, an ethyldiazonium ion is formed, binds DNA, and causes genotoxic damage 27 . Though DNA damage markers such as p-Brca1, p-p53, and p-γH2A.X increased after DEN, the magnitude of induction was similar between groups (Extended Fig. 7d , e). Altogether, livers with altered ploidy did not exhibit differential xenobiotic metabolism, oxidative stress, or DNA damage responses.
Since the mutagenic activities of DEN were quantitatively similar, it was possible that polyploid cells were buffered from tumor suppressor loss but not oncogene activation. To isolate and test the impact of oncogene activation in mice with different levels of polyploidy, we overexpressed MYC using a liver specific driver (LAP-tTa) and a dox-inducible promoter (TRE-MYC) (Extended Data Fig. 8a ) 29 . Prior to inducing MYC overexpression, we gave LAP-tTA; TRE-MYC mice four doses of siRNA to transiently alter ploidy ( Fig. 5a ). At P30, significant differences in ploidy, but not MYC expression levels, were observed (Extended Data Fig. 8b, c) . Dox withdrawal at P25 leads to transformation of less than 1% of MYC expressing cells, a dynamic range that allowed us to sensitively quantitate the influence of ploidy on tumor initiation. Nine weeks post-induction, tumor development and liver to body weight ratios were indistinguishable between siRNA treated ploidy groups (Fig. 5b) , showing that ploidy had little impact on MYC oncogene induced tumorigenesis.
It remained possible that the impact of DEN-induced oncogene activation was agnostic to ploidy, but that DEN induced tumor suppressor loss of heterozygosity (LOH) is more difficult to achieve in hepatocytes with wholesale genome duplications. To quantitate the dynamics of tumor suppressor loss, we engineered an adenovirus carrying Cas9 and a guide strand RNA targeting
Pten (Ad-Cas9-sgPten) (sgRNA was validated in reference 30 ), a commonly inactivated tumor suppressor gene in HCC. 15 days after IV Ad-Cas9-sgPten delivery into mice with different levels of ploidy, Pten LOH was assessed with immunohistochemistry ( Fig. 5c ). The frequency of hepatocytes with complete Pten deletion was inversely proportional to the extent of polyploidy ( Fig. 5d , Extended Data Fig. 8d ). After 110 days, this effect was even more pronounced ( Fig. 5e , Extended Data Fig. 8e ). To confirm that the degree of ploidy did not change susceptibility to adenoviral infection, we verified that equal numbers of cells expressed GFP after Adenovirus-GFP delivery (Extended Data Fig. 8f ). To rule out the possibility of a Pten specific-phenomenon, we also assessed Apc, a tumor suppressor in the WNT pathway. We injected an Adenoassociated virus carrying a guide strand against exon 8 of Apc (AAV-sgApc) into dox-inducible
Cas9 mice (Rosa-rtTa; TRE-Cas9) subjected to siRNA induced ploidy changes ( Fig. 5f ). In vitro, this particular sgApc effectively mutagenized Apc (Extended Data Fig. 8g ) and had previously been used to generate Apc null hepatocytes 31 . To quantitate the number of Apc null clones in vivo, we probed for ectopic Glutamine Synthetase (GS), a specific and sensitive marker of aberrant WNT activation in the liver 32 . Strikingly, hyperdiploid livers were much more susceptible to Apc LOH than control livers, and hyperpolyploid livers harbored the fewest GS+ cells (Fig. 5g ).
These data support the concept that polyploid livers are protected from tumor suppressor loss and are not more sensitive to oncogene activation.
Reduced susceptibility to tumor suppressor LOH paired with reduced tumorigenesis in hyperpolyploid livers suggested that DEN-induced HCCs were in large part dependent on tumor suppressor loss. Previously, DEN was shown to preferentially select for oncogenic mutations (Hras and Ctnnb1) in studies focused on identifying mutations in these pathways 33, 34 . We aimed to more broadly and thoroughly map the mutational landscape of these tumors, so we sequenced 242 of the most commonly mutated genes in human and murine HCC in 50 individual DEN induced tumors ( Fig. 6a , Extended Data Table 2 ). We did identify a core group of recurrent, mutually exclusive mutations in oncogenes such as Egfr (Phe254Ile), Hras (Gln61Arg), and Braf (Val637Glu), but a majority of the most commonly mutated genes were bona fide tumor suppressors such as Mll2 (Kmt2d), Brca2, Arid1a, Atm, Apc, and Tsc2. Overall, these data suggest that DEN tumor transformation depends on tumor suppressor loss in addition to EGFR-RAS-MAPK pathway activation, supporting the idea that tumor protection in polyploids is in part mediated through retention of WT tumor suppressor alleles.
Given that the mammalian liver is comprised of a mixture of polyploid and diploid cells, our work would predict that HCCs more likely originate from diploid cells. If this was true, it would follow that HCCs are also more frequently diploid rather than polyploid. We found that even tumors arising from siCtrl mice with polyploid cells were predominantly diploid (Fig. 6b, c) . In human HCCs examined by flow cytometry, 80% of HCCs were comprised of diploid cells [35] [36] [37] .
Altogether, this suggests that human HCCs more likely arise from diploid cells, consistent with the idea that the polyploid state is less compatible with cancer development.
Discussion
The fact that some animals and organs are polyploid, with cells containing whole genome duplications, has perplexed scientists for decades. It is known that 50-80% mammalian hepatocytes are polyploid, and conditions such as chronic hepatitis, steatohepatitis, and oxidative stress have all been associated with increased polyploidy 8, 38 , but it is unknown if ploidy changes represent compensation, cause, or bystander effect of such disease states. Analysis of genetically engineered knockout mice with hyperpolyploid or hyperdiploid livers have not been able to unequivocally link ploidy with cellular fitness, regeneration, or cancer 18, 20 . In part, this is because the reagents used to assess the response of ploidy states to injuries usually confound the effects of ploidy with the effects of the prominent cell cycle genes used to change ploidy.
Here, we devised multiple in vivo methods to transiently alter ploidy in a reversible fashion, such that long-term consequences of such changes could be assessed and compared. In agreement with previous studies 11, 20 , we found that polyploidy had little impact on acute injury or regeneration, but chronically, the polyploid state demonstrated tumor suppressive functions in multiple cancer models. It is interesting that the extent of ploidy increase or decrease in different siRNA, GEMM, and inducible transgenic models appeared to correlate linearly with tumor number and burden. Moreover, we believe that this protection is due in large part to buffering against tumor suppressor loss rather than limiting proliferation after oncogenic insults (Model shown in Fig. 6d ). This is consistent with human data indicating that most HCCs are diploid [35] [36] [37] .
We believed that it was essential to use mouse models to interrogate the role of ploidy in cancer because it is the most rigorous way to examine tumor initiation. For example, in vivo and in vitro human HCCs, which are already transformed, cannot be used to study ploidy's role in the transition state between normal and malignant cells. In addition, we used cancer models that were the most reflective of human disease states. The DEN model generates cancers that are not dependent on singular, artificially strong genetic drivers such as Yap or Akt. Using expression profiling, Snorri Thorgeirsson showed that DEN induced mouse HCCs were more similar to poor survival human HCCs than other mouse cancer models 39 . Also, Allan Balmain's group recently argued for the use of chemically induced mouse cancer models because they more accurately reflect the diverse genomics of human cancers 40 . Indeed, the tumors in our study harbored a wide diversity of oncogenic and tumor suppressor mutations that reflect the biology of human HCCs. The DEN model may mechanistically and genetically reflect the type of liver cancers that arise in humans exposed to mutagens such as aflatoxin, which is a frequent HCC-inducing contaminant of foods in tropical and sub-tropical climates in Africa, Asia and South America 41 . It is conceivable that this unique feature of the liver in part evolved to mitigate the cancer risk associated with these types of common liver mutagens, which frequently induce lethal cancers during the reproductive years. In addition, we showed that polyploid livers are also resistant to high fat induced HCC. These data suggest that the polyploidization associated with non-alcoholic steatohepatitis may represent a protective and tumor suppressive stress response.
In future studies, it would be interesting to determine if there are specific diploid populations in the liver that have greater cancer risk and if this risk can be modulated with ploidy manipulations.
Previously, Wang et al. identified a "stem-like" hepatocyte population around the central vein 14 .
This population of cells repopulated the liver in the absence of injury and were 60% enriched for diploid cells, but it is unknown if the diploid or polyploid cells within this Axin2 compartment have greater self-renewing capacity or tumorigenic potential. It is possible that increasing ploidy in this population might change regenerative capacity or cancer risk. Given that most hepatocytes are capable of extensive proliferation 11, 42 , it is also possible that other diploid populations, whether or not they are stem cells, could respond to distinct liver injuries and contribute to cancer formation.
In this study, we aimed to answer a fundamental question about polyploidy in liver biology, but it is possible that transient or persistent polyploidzation not only serves physiologic functions but could be exploited therapeutically. c. Schema of the Ad-Cas9-sgPten experiment: WT mice were given four doses of siRNA to alter ploidy; two weeks later, adenovirus carrying Cas9 and a guide strand RNA targeting
Figures and legends
Pten (Ad-Cas9-sgPten) was injected into these mice (10 9 pfu/mouse); 15 days or 110 days later, LOH was assessed by Pten immunohistochemistry.
d. Pten staining (left panel) on siAnln and siE2f8 treated livers at 15 days after virus injection.
Red arrowheads point to the cells with Pten deletion, and LOH is quantified in the right panel. Table S1 for sgRNA sequences). These mice were made and maintained in the C3H/HeJ background. TG-shAnln embryonic stem cells were injected by the UTSW Transgenic Core. The strategy was based on work from Scott Lowe's group 26 in this study has been tested as mycoplasma free.
Partial hepatectomy. Surgery was performed as previously described 43 .
High fat diet experiments. High fat diet (HFD) was purchased from RESEARCH DIETS INC.
60% calories were from fat. Animals were kept on HFD from 1.5 to 8 months of age.
Chemical injury experiments. CCl4 is diluted 1:10 in corn oil (Sigma), and administered IP at a dose of 0.5 ml/kg of mouse as described previously 44 . Diethylnitrosomine (DEN, Sigma) is diluted in saline and administered IP at different doses, depending on mouse age. For P19 mice, 25g/g of mouse was injected once; for P24-P27 mice, 75g/g was injected once; for P34 mice, 100g/g was injected once.
Virus experiments. 100µL of Ad-Cas9-sgPten (Vectorbiolabs) was retro-orbitally injected at a dose of 10 9 pfu/mouse. 100µL of Adenovirus-GFP (University of Iowa Viral Vector Core) was retro-orbitally injected at a dose of 1.4 X 10 8 pfu/mouse. 100µL of AAV-sgApc (5 X 10 12 pfu/mouse) was retro-orbitally injected.
RNA Extraction and RT-qPCR. Total RNA was isolated using Trizol reagent (Invitrogen). For qRT-PCR, cDNA synthesis was performed with 1µg of total RNA using iScript Reverse Transcription Kit (Biorad). See Table S1 for primers used in these experiments. Gene expression levels were measured using the Ct method as described previously 45 . following the manufacturer's instructions. Target genes were selected from human HCC and mouse sequencing studies [46] [47] [48] and some well-known cancer related genes. The target probes were synthesized by NuGEN. More than 99.5% of the probes had >90% coverage. The sequencing was performed using a 150 bp single-end protocol on Illumina NextSeq 500 platform.
Sequence processing. BCL files from Illumina Nextseq 500 sequencing were converted to FASTQ files by bcl2fastq (Illumina). After trimming by trim_galore package, BWA-MEM (version 0.7.15) was used to align FASTQ files to reference genome GRCm38 with subsequent processing by Samtools (version 1.3) and Nudup.py (Nugen) to ensure proper file formatting and remove duplicates. Alignments were then recalibrated and realigned by GATK (version 3.5). We acquired 42 million uniquely mapped reads on average for the 53 samples we sequenced with an average on target coverage at 128X and more than 86.6% region has more than 50X coverage.
Identification and annotation of somatic SNVs. To detect somatic variants in tumor samples, we use the somatic variant detection program Mutect (version 1.1.7). 50 tumor samples were called against a panel of 3 normal liver samples from two WT C3HHeJ mice to the reference genome GRCm38. Variants passed the Mutect high-confidence somatic mutation filters were selected and further filtered against from known SNVs in C3HHeJ mice provided by http://ftpmouse.sanger.ac.uk (mgp.v3). SNVs were further annotated using snpEff (version 4.2) and
Variant Effect Predictor. SNVs predicted to have High or Moderate impact were compared to a stringent list of 125 driver genes in human cancer by Vogelstein et al 49 to map putative driver genes and mutations. The mutation landscape was graphed by using GenVisR (a package from R Bioconductor) waterfall plot algorithm on putative driver genes for all 50 tumor samples ( Fig.   6a ).
Statistical analysis. The sample size was determined by producing a confidence interval estimate with a specified margin of error to ensure that a test of hypothesis has a high probability of detecting a meaningful difference in the parameter. The data in most figure panels reflect multiple experiments performed on different days using mice derived from different litters.
Variation is indicated using standard error presented as mean ± SEM. The variances of two groups that are being compared are similar. Two-tailed Student's t-tests (two-sample equal variance) were used to test the significance of differences between two groups. Statistical significance is displayed as p < 0.05 (*) or p < 0.01 (**) unless specified otherwise. The investigators were blinded during the processes of mice treatments and data analysis. Image analysis for the quantification of cell proliferation, Pten deletion, GFP+ cells, liver surface tumor and malignant nodule numbers were performed in a blinded fashion.
Data availability. The DEN tumor DNA targeted sequencing data was reported in Figure 6a and Extended Data Table 2 . The source dataset for the data reported in this Figure will be made available at publication or earlier if requested.
